MedPath

D-chiro-Inositol in Overweight Type 1 Diabetes Patients

Phase 3
Completed
Conditions
Type 1 Diabetes
Registration Number
NCT02730949
Lead Sponsor
Campus Bio-Medico University
Brief Summary

The purpose of this pilot study was to evaluate the effect of D-chiro-Inositol (DCI) oral supplementation in addiction to folic acid compared to folic acid alone on glycaemic control as assessed by HbA1c in overweight or obese T1D patients undergoing intensive insulin therapy.

A 24 weeks, prospective, randomized control trial was carried out in T1D patients, aged 17-50 years (13 males, 13 females), with disease duration \> 1 year and BMI \>25, attending as outpatients the Endocrinology and Diabetes Unit of University Campus Bio-Medico in Rome

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • T1D patients
  • aged 17-50 years
  • disease duration > 1 year
  • BMI >25
Exclusion Criteria
  • learning disabilities
  • presence of chronic conditions potentially able to influence daily activities (visual or auditory disability, motor impairment for neurological or orthopaedic problems).
  • T1D patients affected from diabetic complications
  • pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
efficacy of DCI oral supplementation on metabolic control6 months

efficacy of DCI oral supplementation on metabolic control as assessed by HbA1c (%)

Secondary Outcome Measures
NameTimeMethod
Insulin Requirement (I.R.) IU/kg6 months

reduction of I.R.

BMI kg/m26 months

reduction of BMI

Trial Locations

Locations (1)

University Campus Bio Medico

🇮🇹

Rome, Italy

University Campus Bio Medico
🇮🇹Rome, Italy

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.